-
公开(公告)号：US20060240006A1
公开(公告)日：2006-10-26
申请号：US11111098
申请日：2005-04-20
申请人： Chishih Chu , Li-Te Chin , Shu-Ching Hsu
发明人： Chishih Chu , Li-Te Chin , Shu-Ching Hsu
IPC分类号： G01N33/567 , A61K39/395 , C07K16/28
CPC分类号： C07K16/2818 , C07K2317/21
摘要： In order to provide necessary information for the production of complete human monoclonal antibodies capable of human CD152 (CTLA-4) binding, the primary structures of heavy and light chains have been elucidated. The novel amino acid sequence of identified heavy and light chains are derived from VH3 and Vλ germline genes, respectively. Antibodies comprising such novel structures cause specific binding to soluble recombinant human CD152 as well as to activated human peripheral T cells, where the expression of CD152 has been elevated.
-
2.发明申请Complete human monoclonal IgG4lambda specific for CTLA-4 and uses thereof for detection of soluble CTLA-4 and isolation of regulatory cells 审中-公开完整的针对CTLA-4的人单克隆IgG4l1及其用于检测可溶性CTLA-4和分泌调节细胞的用途公开(公告)号：US20120009207A1
公开(公告)日：2012-01-12
申请号：US13107504
申请日：2011-05-13
申请人： Li-Te CHIN , Shu-Ching Hsu
发明人： Li-Te CHIN , Shu-Ching Hsu
CPC分类号： A61K35/26 , A61K38/17 , C07K16/2818 , C07K2317/34 , C07K2317/92 , G01N33/505
摘要： The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.
摘要翻译： 本发明提供了完全人抗体性质的CTLA-4非阻断剂，因此在人体中是非免疫原性的。 使用这种非阻断剂的免疫测定方法测量人受试者样品中的CTLA-4含量。 本发明还提供了一种分离人类调节性T细胞的新方法。 所产生的富含和消耗的细胞群可用于治疗或改善人类疾病。
-
3.发明授权公开(公告)号：US08021860B2
公开(公告)日：2011-09-20
申请号：US12318679
申请日：2009-01-06
申请人： Li-Te Chin , Shu-Ching Hsu
发明人： Li-Te Chin , Shu-Ching Hsu
IPC分类号： C12P21/04
CPC分类号： G01N33/5052 , A61K2039/505 , C07K16/00 , C07K16/2818 , C07K2317/73 , C07K2317/74 , G01N33/505 , G01N33/6854 , G01N2333/70521
摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。
-
4.发明申请Method For Producing Human Antibodies With Properties Of Agonist, Antagonist, or Inverse Agonist 有权用激动剂，拮抗剂或反激动剂的性质产生人类抗体的方法公开(公告)号：US20110033895A1
公开(公告)日：2011-02-10
申请号：US12888713
申请日：2010-09-23
申请人： Li-Te CHIN , Shu-Ching Hsu
发明人： Li-Te CHIN , Shu-Ching Hsu
IPC分类号： C12P21/08
CPC分类号： G01N33/5052 , A61K2039/505 , C07K16/00 , C07K16/2818 , C07K2317/73 , C07K2317/74 , G01N33/505 , G01N33/6854 , G01N2333/70521
摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。
-
5.发明申请Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist 有权用于产生具有激动剂，拮抗剂或反向激动剂的性质的人抗体的方法公开(公告)号：US20090286224A1
公开(公告)日：2009-11-19
申请号：US12318679
申请日：2009-01-06
申请人： Li-Te Chin , Shu-Ching Hsu
发明人： Li-Te Chin , Shu-Ching Hsu
CPC分类号： G01N33/5052 , A61K2039/505 , C07K16/00 , C07K16/2818 , C07K2317/73 , C07K2317/74 , G01N33/505 , G01N33/6854 , G01N2333/70521
摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。
-
6.发明授权公开(公告)号：US10174109B2
公开(公告)日：2019-01-08
申请号：US15798478
申请日：2017-10-31
申请人： Li-Te Chin , Shu-Ching Hsu , Kai-Chen Wang
发明人： Li-Te Chin , Shu-Ching Hsu , Kai-Chen Wang
摘要： The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.
-
7.发明授权公开(公告)号：US09840555B2
公开(公告)日：2017-12-12
申请号：US14526842
申请日：2014-10-29
申请人： Li-Te Chin , Shu-Ching Hsu , Kai-Chen Wang
发明人： Li-Te Chin , Shu-Ching Hsu , Kai-Chen Wang
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/76
摘要： The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.
-
公开(公告)号：US07968300B2
公开(公告)日：2011-06-28
申请号：US11943682
申请日：2007-11-21
申请人： Li-Te Chin , Shu-Ching Hsu
发明人： Li-Te Chin , Shu-Ching Hsu
IPC分类号： G01N33/53
CPC分类号： A61K35/26 , A61K38/17 , C07K16/2818 , C07K2317/34 , C07K2317/92 , G01N33/505
摘要： The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.
摘要翻译： 本发明提供了完全人抗体性质的CTLA-4非阻断剂，因此在人体中是非免疫原性的。 使用这种非阻断剂的免疫测定方法测量人受试者样品中的CTLA-4含量。 本发明还提供了一种分离人类调节性T细胞的新方法。 所产生的富含和贫化的细胞群可用于治疗或改善人类疾病。
-
9.发明授权Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist 有权用于产生具有激动剂，拮抗剂或反向激动剂的性质的人抗体的方法公开(公告)号：US08158386B2
公开(公告)日：2012-04-17
申请号：US12888713
申请日：2010-09-23
申请人： Li-Te Chin , Shu-Ching Hsu
发明人： Li-Te Chin , Shu-Ching Hsu
IPC分类号： G01N33/567
CPC分类号： G01N33/5052 , A61K2039/505 , C07K16/00 , C07K16/2818 , C07K2317/73 , C07K2317/74 , G01N33/505 , G01N33/6854 , G01N2333/70521
摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。
-
10.发明授权Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist 有权用激活剂，拮抗剂或反向激动剂的性质产生人CD152的人抗体的方法公开(公告)号：US07494779B2
公开(公告)日：2009-02-24
申请号：US10866120
申请日：2004-06-14
申请人： Li-Te Chin , Shu-Ching Hsu
发明人： Li-Te Chin , Shu-Ching Hsu
IPC分类号： G01N33/53
CPC分类号： G01N33/5052 , A61K2039/505 , C07K16/00 , C07K16/2818 , C07K2317/73 , C07K2317/74 , G01N33/505 , G01N33/6854 , G01N2333/70521
摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.018 秒)
